Phase 2
Completed N=62
Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine
Source: ClinicalTrials.gov NCT03527238 ↗Enrolled (actual)
62
Serious AEs
0.0%
Results posted
Dec 2021
Primary outcomePrimary: Tacrolimus Target Trough Level Maintenance — 38.4; 24.2 percentage of days
Summary
Clinical trial applying Phenotypic Precision Medicine (PPM) to tacrolimus dosing in liver and/or kidney transplant recipients to show improvement in maintaining drug trough levels within the target range.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Tacrolimus Target Trough Level Maintenance |
38.4; 24.2 | — |
Eligibility Criteria
Inclusion Criteria
- adults undergoing liver and/or kidney transplantation
Exclusion Criteria
- transplant patients with contraindications to tacrolimus
Data sourced from ClinicalTrials.gov (NCT03527238). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.